Eli Lilly & Co., Worldwide Rights To A Series Of Novel Pre-Clinical Compounds
Eli Lilly and Company, commonly known as Eli Lilly, is a prominent global pharmaceutical firm headquartered in the United States. Founded in 1876, the company has established itself as a leader in the biopharmaceutical industry, focusing on innovative treatments across various therapeutic areas, including oncology, diabetes, and immunology.
With a strong presence in North America, Europe, and Asia, Eli Lilly is renowned for its commitment to research and development, particularly in novel pre-clinical compounds. The company’s core products, such as insulin and cancer therapies, are distinguished by their efficacy and patient-centric approach.
Eli Lilly's notable achievements include pioneering advancements in diabetes care and maintaining a robust pipeline of potential therapies, solidifying its position as a key player in the global healthcare landscape.
Part of the Sustainability team at Eli Lilly & Co., Worldwide Rights To A Series Of Novel Pre-Clinical Compounds?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Reported emissions
No reported emissions data is available for Eli Lilly & Co., Worldwide Rights To A Series Of Novel Pre-Clinical Compounds yet.
Eli Lilly & Co., Worldwide Rights To A Series Of Novel Pre-Clinical Compounds's reported carbon emissions
Eli Lilly & Co., Worldwide Rights To A Series Of Novel Pre-Clinical Compounds, currently does not have specific carbon emissions data available for the most recent year. The organisation is part of a corporate family that cascades emissions data from Thermo Fisher Scientific Inc., which is at cascade level 6. However, no specific emissions figures or reduction targets have been provided.
In terms of climate commitments, Eli Lilly & Co. has not outlined any specific reduction initiatives or targets, such as those set by the Science Based Targets initiative (SBTi). The absence of documented reduction targets suggests that the company may still be in the early stages of formalising its climate strategy.
As a merged entity, Eli Lilly & Co. may benefit from the climate initiatives and commitments of its parent organisation, Thermo Fisher Scientific Inc. However, without explicit data or targets, it is challenging to assess the company's current carbon footprint or its long-term climate strategy.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
Eli Lilly & Co., Worldwide Rights To A Series Of Novel Pre-Clinical Compounds’s Climate Goals (2030 & 2050)
No climate goals have been disclosed for Eli Lilly & Co., Worldwide Rights To A Series Of Novel Pre-Clinical Compounds yet.
Scope 3 top emissions categories
No scope 3 category breakdown has been disclosed yet.
Climate initiatives
Science Based Targets Initiative
Inherited from Thermo Fisher Scientific Inc.
Carbon Disclosure Project
Inherited from Thermo Fisher Scientific Inc.
The Climate Pledge
UN Global Compact Climate Champions initiative
Inherited from Thermo Fisher Scientific Inc.
RE 100
Climate Action 100
Emissions comparison with industry peers
View similar organisationsNo peer comparison is available for Eli Lilly & Co., Worldwide Rights To A Series Of Novel Pre-Clinical Compounds yet.
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn moreCurious to see your top suppliers emissions?
Book a demo for a pilot project